Meta-Analysis
Copyright ©The Author(s) 2017.
World J Gastroenterol. Sep 21, 2017; 23(35): 6516-6533
Published online Sep 21, 2017. doi: 10.3748/wjg.v23.i35.6516
Table 3 Sensitivity analysis and subgroup analysis
VariablesNo. of studiesOR=[95%CI]P1 valueI2 (%)
Sensitivity analysis
Overall biliary complication1.75 [0.89-3.43]0.1054
Omitting Sanchez et al[41]71.52 [1.01-2.28]0.040
Omitting Cacciarelli et al[16]71.81 [0.87-3.76]0.1161
Omitting Heffron et al[38]71.86 [0.87-3.95]0.1160
Omitting Toso et al[20]71.86 [0.84-4.13]0.1360
Omitting Iwamoto et al[36]71.81 [0.84-3.92]0.1361
Omitting Shen et al[33]71.89 [0.90-3.96]0.0959
Omitting Lee et al[32]71.69 [0.72-3.94]0.2356
Omitting Kim et al[29]72.07 [0.98-4.37]0.0650
Bile leak1.85 [0.46-7.39]0.3953
Omitting Sanchez et al[41]20.98 [0.38-2.49]0.960
Omitting Kim et al[30]22.47 [0.19-31.38]0.4977
Omitting Kim et al[29]23.62 [0.53-24.77]0.1946
Biliary stricture1.37 [0.70-2.70]0.3647
Omitting Sanchez et al[41]51.28 [0.62-2.62]0.5154
Omitting Lo et al[40]51.11 [0.54-2.26]0.7842
Omitting Ikegami et al[31]51.55 [0.71-3.39]0.2749
Omitting Kim et al[30]51.47 [0.74-2.95]0.2751
Omitting Kim et al[29]51.72 [0.91-3.25]0.0928
Omitting Song et al[28]51.20 [0.43-3.31]0.7349
Subgroup analysis
1-yr graft survival0.66 [0.57-0.76]< 0.00136
Rituximab for ABO-I LT (yes/no)4 vs 70.88 [0.58-1.33] vs 0.44 [0.20-0.66]0.020 vs 49
Living donor (yes/no)4 vs 120.79 [0.56-1.13] vs 0.64 [0.55-0.74]0.270 vs 44
Urgent indication (yes/no)8 vs 80.37 [0.23-0.59] vs 0.70 [0.61-0.81]0.0127 vs 8
Pediatric2 (yes/no)5 vs 120.88 [0.68-1.15] vs 0.59 [0.50-0.69]0.0112 vs 45
3-yr graft survival0.74 [0.64-0.85]< 0.0010
Rituximab for ABO-I LT (yes/no)3 vs 30.81 [0.56-1.18] vs 0.60 [0.26-1.41]0.530 vs 0
Living donor (yes/no)2 vs 50.84 [0.57-1.25] vs 0.72 [0.62-0.84]0.470 vs 0
Urgent indication (yes/no)3 vs 40.59 [0.27-1.31] vs 0.74 [0.64-0.86]0.580 vs 0
Pediatric2 (yes/no)3 vs 50.95 [0.71-1.26] vs 0.67 [0.57-0.80]0.040 vs 0
5-yr graft survival0.75 [0.66-0.86]< 0.0010
Rituximab for ABO-I LT (yes/no)3 vs 20.96 [0.66-1.39] vs 0.56 [0.33-0.96]0.110 vs 0
Living donor (yes/no)4 vs 40.83 [0.61-1.14] vs 0.73 [0.63-0.86]0.4610 vs 0
Urgent indication (yes/no)3 vs 50.60 [0.26-1.39] vs 0.76 [0.66-0.87]0.60 vs 0
Pediatric 2 (yes/no)2 vs 70.82 [0.63-1.07] vs 0.73 [0.62-0.86]0.4442 vs 0
10-yr graft survival0.80 [0.69-0.93]0.00469
Rituximab for ABO-I LT (yes/no)0 vs 1NA vs 0.51 [0.31-0.85]NANA
Living donor (yes/no)1 vs 10.51 [0.31-0.85] vs 0.84 [0.71-0.98]0.07NA vs NA
Urgent indication (yes/no)0 vs 2NA vs 0.70 [0.44-1.11]NANA vs 69
Pediatric 2 (yes/no)2 vs 10.71 [0.41-1.23] vs 0.81 [0.70-0.98]0.6572 vs NA
1-yr patient survival0.88 [0.67-1.16]0.380
Rituximab for ABO-I LT (yes/no)4 vs 70.88 [0.59-1.31] vs 0.67 [0.44-1.04]0.380 vs 0
Living donor (yes/no)4 vs 110.79 [0.56-1.13] vs 1.04 [0.67-1.61]0.350 vs 9
Urgent indication (yes/no)8 vs 70.93 [0.56-1.52] vs 0.87 [0.62-1.20]0.830 vs 21
Pediatric (yes/no)4 vs 110.64 [0.38-1.09] vs 0.98 [0.71-1.35]0.180 vs 5
3-yr patient survival0.89 [0.64-1.23]0.470
Rituximab for ABO-I LT (yes/no)4 vs 30.90 [0.64-1.27] vs 0.80 [0.31-2.06]0.820 vs 43
Living donor (yes/no)3 vs 40.91 [0.64-1.32] vs 0.78 [0.38-1.62]0.715 vs 15
Urgent indication (yes/no)3 vs 40.81 [0.35-1.91] vs 0.90 [0.63-1.28]0.8343 vs 0
Pediatric (yes/no)2 vs 50.46 [0.15-1.38] vs 0.94 [0.67-1.32]0.2218 vs 0
5-yr patient survival0.89 [0.66-1.20]0.4517
Rituximab for ABO-I LT (yes/no)2 vs 20.89 [0.61-1.31] vs 1.00 [0.20-5.08]0.890 vs 57
Living donor (yes/no)3 vs 30.79 [0.57-1.08] vs 2.38 [0.86-6.63]0.040 vs 0
Urgent indication (yes/no)3 vs 32.38 [0.86-6.63] vs 0.79 [0.57-1.08]0.040 vs 0
Pediatric (yes/no)1 vs 50.58 [0.32-1.02] vs 1.04 [0.72-1.48]0.09NA vs 0
10-yr patient survival0.46 [0.28-0.78]0.0047
Rituximab for ABO-I LT (yes/no)0 vs 1NA vs 0.46 [0.28-0.78]NANA
Living donor (yes/no)1 vs 00.46 [0.28-0.78] vs NANANA
Urgent indication (yes/no)0 vs 1NA vs 0.46 [0.28-0.78]NANA
Pediatric (yes/no)1 vs 00.46 [0.28-0.78] vs NANANA
ACR1.23 [0.93-1.62]0.150
Rituximab for ABO-I LT (yes/no)5 vs 50.86 [0.57-1.30] vs 1.61 [1.01-2.58]0.0480 vs 0
Living donor (yes/no)4 vs 90.87 [0.58-1.32] vs 1.69 [1.14-2.50]0.020 vs 0
Urgent indication (yes/no)6 vs 71.56 [0.96-2.53] vs 1.08 [0.77-1.53]0.230 vs 22
Pediatric (yes/no)3 vs 101.64 [0.82-3.29] vs 1.16 [0.85-1.57]0.370 vs 0
CR2.28 [1.00-5.22]0.0542
Rituximab for ABO-I LT (yes/no)2 vs 26.45 [0.13-333.04] vs 2.64 [0.83-8.44]0.6780 vs 0
Living donor (yes/no)2 vs 26.45 [0.13-333.04] vs 2.64 [0.83-8.44]0.6780 vs 0
Urgent indication (yes/no)2 vs 22.64 [0.83-8.44] vs 6.45 [0.13-333.04]0.670 vs 80
Pediatric (yes/no)0 vs 4NA vs 2.28 [1.00-5.22]NANA vs 42
AMR74.21 [16.32-337.45]< 0.00112
Rituximab for ABO-I LT (yes/no)2 vs 148.32 [ 2.31-1011.61] vs 245.87 [13.04-4636.62]0.4553 vs NA
Living donor (yes/no)1 vs 3208.48 [12.49-3479.38] vs 35.81 [6.02-212.88]0.3NA vs 18
Urgent indication (yes/no)3 vs 135.81 [ 6.02-212.88] vs 208.48 [12.49-3479.38]0.318 vs NA
Pediatric (yes/no)0 vs 4NA vs 74.21 [16.32-337.45]NANA vs 12
Bacterial infection0.72 [0.46-1.14]0.160
Rituximab for ABO-I LT (yes/no)4 vs 00.72 [0.46-1.14] vs NANA0 vs NA
Living donor (yes/no)3 vs 10.70 [0.42-1.15] vs 0.84 [0.29-2.45]0.750 vs NA
Urgent indication (yes/no)1 vs 30.84 [0.29-2.45] vs 0.70 [0.42-1.15]0.75NA vs 0
Pediatric (yes/no)0 vs 4NA vs 0.72 [0.46-1.14]NANA vs 0
Fungal infection0.66 [0.37-1.18]0.160
Rituximab for ABO-I LT (yes/no)3 vs 00.78 [0.42-1.44] vs NANA0 vs NA
Living donor (yes/no)2 vs 20.65 [0.31-1.33] vs 0.63 [0.09-4.40]0.990 vs 62
Urgent indication (yes/no)2 vs 20.63 [0.09-4.40] vs 0.65 [0.31-1.33]0.9962 vs 0
Pediatric (yes/no)0 vs 4NA vs 0.71 [0.39-1.28]NANA vs 0
CMV infection2.64 [1.63-4.29]< 0.00143
Rituximab for ABO-I LT (yes/no)3 vs 02.2 [1.23-3.93] vs NANA4 vs NA
Living donor (yes/no)3 vs 22.25 [1.24-4.09] vs 6.43 [0.17-242.88]0.584 vs 82
Urgent indication (yes/no)1 vs 41.45 [0.45-4.74] vs 2.77 [1.12-6.86]0.4NA vs 53
Pediatric (yes/no)0 vs 5NA vs 2.64 [1.63-4.29]NANA vs 43
Overall Biliary complication1.75 [0.89-3.43]0.154
Rituximab for ABO-I LT (yes/no)3 vs 21.38 [0.62-3.07] vs 1.25 [0.35-4.51]0.8951 vs 0
Living donor (yes/no)3 vs 51.52 [0.74-3.10] vs 2.36 [0.63-8.87]0.5746 vs 66
Urgent indication (yes/no)2 vs 61.23 [0.48-3.21] vs 2.08 [0.85-5.07]0.440 vs 66
Pediatric (yes/no)2 vs 61.25 [0.35-4.51] vs 1.95 [0.85-4.46]0.570 vs 67
Bile leak1.85 [0.46-7.39]0.3953
Rituximab for ABO-I LT (yes/no)2 vs 00.96 [0.38-2.46] vs NANA0 vs NA
Living donor (yes/no)2 vs 10.98 [0.38-2.49] vs 10.82 [1.17-100.44]0.0510 vs NA
Urgent indication (yes/no)0 vs 3NA vs 1.85 [0.46-7.39]NANA vs 53
Pediatric (yes/no)0 vs 3NA vs 1.85 [0.46-7.39]NANA vs 53
Biliary stricture1.37 [0.70-2.70]0.3647
Rituximab for ABO-I LT (yes/no)4 vs 11.00 [0.46-2.15] vs 4.32 [1.18-15.81]0.0652 vs NA
Living donor (yes/no)4 vs 21.00 [0.46-2.15] vs 4.49 [1.36-14.87]0.0452 vs 0
Urgent indication (yes/no)1 vs 54.32 [1.18-15.81] vs 1.44 [1.04-1.99]0.11NA vs 42
Pediatric (yes/no)0 vs 6NA vs 1.52 [1.11-2.08]NANA vs 47
HV complication1.60 [0.64-4.00]0.32NA
Rituximab for ABO-I LT (yes/no)1 vs 01.60 [0.64-4.00] vs NANANA
Living donor (yes/no)1 vs 01.60 [0.64-4.00] vs NANANA
Urgent indication (yes/no)0 vs 1NA vs 1.60 [0.64-4.00]NANA
Pediatric (yes/no)0 vs 1NA vs 1.60 [0.64-4.00]NANA
PV complication1.83 [0.70-4.76]0.220
Rituximab for ABO-I LT (yes/no)3 vs 11.19 [0.31-4.65] vs 2.65 [0.29-24.07]0.550 vs NA
Living donor (yes/no)3 vs 21.19 [0.31-4.65] vs 3.27 [0.82-13.07]0.310 vs 0
Urgent indication (yes/no)2 vs 33.27 [0.82-13.07] vs 1.19 [0.31-4.65]0.310 vs 0
Pediatric (yes/no)0 vs 5NA vs 1.83 [0.70-4.76]NANA vs 0
HA complication4.17 [2.26-7.67]< 0.0010
Rituximab for ABO-I LT (yes/no)3 vs 32.52 [0.68-9.27] vs 4.43 [0.90-21.87]0.590 vs 53
Living donor (yes/no)4 vs 53.62 [1.20-10.91] vs 4.44 [2.13-9.25]0.760 vs 10
Urgent indication (yes/no)3 vs 65.50 [2.33-13.00] vs 3.30 [1.39-7.83]0.410 vs 0
Pediatric (yes/no)1 vs 80.47 [0.03-8.56] vs 5.26 [2.73-10.14]0.11NA vs 0